209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1).
Saved in:
| Title: | 209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). |
|---|---|
| Authors: | Besse, B.1 (AUTHOR), Springfeld, C.2 (AUTHOR), Baik, C.3 (AUTHOR), Hervieu, A.4 (AUTHOR), Solomon, B.5 (AUTHOR), Moreno, V.6 (AUTHOR), Bazhenova, L.7 (AUTHOR), Goto, K.8 (AUTHOR), Kim, Y.C.9 (AUTHOR), Lu, S.10 (AUTHOR), Sun, M.11 (AUTHOR), Trone, D.12 (AUTHOR), Thamake, S.12 (AUTHOR), Cho, B.C.13 (AUTHOR), de Langen, A.14 (AUTHOR), Popat, S.15 (AUTHOR), Wolf, J.16 (AUTHOR), Moro-Sibilot, D.17 (AUTHOR), Fang, J.18 (AUTHOR), Drilon, A.19 (AUTHOR) |
| Source: | European Journal of Cancer. 2022 Supplement 1, Vol. 174, pS75-S76. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
